Rocket Pharmaceuticals Appoints Jessie Yeung as Vice President of Investor Relations and Corporate Finance
March 08 2022 - 7:00AM
Business Wire
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage
company advancing an integrated and sustainable pipeline of genetic
therapies for rare childhood disorders, today announces the
appointment of Jessie Yeung as Vice President of Investor Relations
and Corporate Finance. Ms. Yeung brings more than 15 years of
investor relations, corporate finance and capital market experience
across industries including the biopharmaceutical and financial
sectors. She will be responsible for leading the investor relations
function and capital markets strategy.
“I’m thrilled to welcome Jessie to Rocket as we continue to
advance our world-class pipeline of gene therapy clinical programs
and move toward multiple key milestones as a Company, including our
first top-line readouts this year,” said Gaurav Shah, Chief
Executive Officer of Rocket Pharma. “Jessie’s breadth of
relationships and experience with the investor community and wealth
of finance expertise will be invaluable for our investors, existing
and new, as we continue our growth trajectory. Jessie’s leadership
will be instrumental in communicating Rocket’s unique approach to
gene therapy and progress in our relentless pursuit of innovative
gene therapy cures for rare and devastating diseases.”
Prior to joining Rocket, Ms. Yeung was the Head of Corporate
Finance and Investor Relations at Legend Biotech. There, she
developed the company’s comprehensive investor relations strategy
leading to exceptional investor relationships, while also helping
raise over $1 billion through private placements and public
offerings as well as launching the largest biotech IPO of 2020.
Prior to Legend Biotech, she covered the large-cap biotechnology
sector as an equity research analyst at Bank of America Merrill
Lynch, as well as the pharmaceuticals sector at Wells Fargo and
consumer retail sector while at J.P. Morgan. During her tenure in
equity research, Ms. Yeung developed an extensive network of
investors. Earlier in her career, Ms. Yeung was with J.P. Morgan
for over 10 years, where she held corporate finance roles including
financial planning and analysis, product and valuation control,
business development and risk management.
“It’s a tremendous honor to join the passionate and talented
team at Rocket, given its unique and exciting pipeline of
multi-platform clinical programs and leadership in the fast-growing
field of gene therapy,” said Ms. Yeung. “I’m excited to continue to
engage with the investment community to tell Rocket’s story and
create long-term value for shareholders.”
Ms. Yeung earned her bachelor’s degree in Business
Administration from Carnegie Mellon University and MBA from
Columbia Business School.
About Rocket Pharmaceuticals, Inc.
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) is advancing an
integrated and sustainable pipeline of genetic therapies that
correct the root cause of complex and rare childhood disorders. The
Company’s platform-agnostic approach enables it to design the best
therapy for each indication, creating potentially transformative
options for patients afflicted with rare genetic diseases. Rocket's
clinical programs using lentiviral vector (LVV)-based gene therapy
are for the treatment of Fanconi Anemia (FA), a difficult to treat
genetic disease that leads to bone marrow failure and potentially
cancer, Leukocyte Adhesion Deficiency-I (LAD-I), a severe pediatric
genetic disorder that causes recurrent and life-threatening
infections which are frequently fatal, and Pyruvate Kinase
Deficiency (PKD), a rare, monogenic red blood cell disorder
resulting in increased red cell destruction and mild to
life-threatening anemia. Rocket’s first clinical program using
adeno-associated virus (AAV)-based gene therapy is for Danon
Disease, a devastating, pediatric heart failure condition. For more
information about Rocket, please visit www.rocketpharma.com.
Rocket Cautionary Statement Regarding Forward-Looking
Statements
Various statements in this release concerning Rocket’s future
expectations, plans and prospects, including without limitation,
Rocket’s expectations regarding its guidance for 2022 in light of
COVID-19, the safety and effectiveness of product candidates that
Rocket is developing to treat Fanconi Anemia (FA), Leukocyte
Adhesion Deficiency-I (LAD-I), Pyruvate Kinase Deficiency (PKD),
and Danon Disease, the expected timing and data readouts of
Rocket’s ongoing and planned clinical trials, Rocket’s plans for
the advancement of its Danon Disease program following the lifting
of the FDA’s clinical hold and the safety, effectiveness and timing
of related pre-clinical studies and clinical trials, may constitute
forward-looking statements for the purposes of the safe harbor
provisions under the Private Securities Litigation Reform Act of
1995 and other federal securities laws and are subject to
substantial risks, uncertainties and assumptions. You should not
place reliance on these forward-looking statements, which often
include words such as "believe," "expect," "anticipate," "intend,"
"plan," "will give," "estimate," "seek," "will," "may," "suggest"
or similar terms, variations of such terms or the negative of those
terms. Although Rocket believes that the expectations reflected in
the forward-looking statements are reasonable, Rocket cannot
guarantee such outcomes. Actual results may differ materially from
those indicated by these forward-looking statements as a result of
various important factors, including, without limitation, Rocket’s
ability to monitor the impact of COVID-19 on its business
operations and take steps to ensure the safety of patients,
families and employees, the interest from patients and families for
participation in each of Rocket’s ongoing trials, our expectations
regarding the delays and impact of COVID-19 on clinical sites,
patient enrollment, trial timelines and data readouts, our
expectations regarding our drug supply for our ongoing and
anticipated trials, actions of regulatory agencies, which may
affect the initiation, timing and progress of pre-clinical studies
and clinical trials of its product candidates, Rocket’s dependence
on third parties for development, manufacture, marketing, sales and
distribution of product candidates, the outcome of litigation, and
unexpected expenditures, as well as those risks more fully
discussed in the section entitled "Risk Factors" in Rocket’s
Quarterly Report on Form 10-Q for the quarter ended September 30,
2021, filed November 5, 2021 with the SEC. Accordingly, you should
not place undue reliance on these forward-looking statements. All
such statements speak only as of the date made, and Rocket
undertakes no obligation to update or revise publicly any
forward-looking statements, whether as a result of new information,
future events or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220308005474/en/
Media Kevin Giordano Director, Corporate Communications
kgiordano@rocketpharma.com
Investors Jessie Yeung, M.B.A. Vice President, Investor
Relations and Corporate Finance investors@rocketpharma.com
Mayur Kasetty, M.D., M.B.A. Director, Business Development &
Operations investors@rocketpharma.com
Rocket Pharmaceuticals (NASDAQ:RCKT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Rocket Pharmaceuticals (NASDAQ:RCKT)
Historical Stock Chart
From Apr 2023 to Apr 2024